Timelines of translational science: From technology initiation to FDA approval
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
While timelines for clinical development have been extensively studied, there is little data on the broader path from initiation of research on novel drug targets, to approval of drugs based on this research. We examined timelines of translational science for 138 drugs and biologicals approved by the FDA from 2010-2014 using an analytical model of technology maturation. Research on targets for 102 products exhibited a characteristic (S-curve) maturation pattern with exponential growth between statistically defined technology initiation and established points. The median initiation was 1974, with a median of 25 years to the established point, 28 years to first clinical trials, and 36 years to FDA approval. No products were approved before the established point, and development timelines were significantly longer when the clinical trials began before this point (11.5 vs 8.5 years, p<0.0005). Technological maturation represents the longest stage of translation, and significantly impacts the efficiency of drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“The problem is well documented; the annual number of approvals of New Molecular Entities (NMEs) has been static [1], clinical development pipelines continue to have high attrition rates [2], and drug development costs are increasing exponentially [3].”
BackgroundHow were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 1×
“More research is required to fully understand how the maturity of the target technology, the maturation of technologies related to the chemical entity, and other information known to be associated drug development such as Lipinski’s “rule of 5” [30] and AstraZeneca’s “5 R’s” [31],collectively contribute to the probabi…”
BackgroundThe discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514 · cited 1×
“examined the interval from selected publications that described target or lead identification, to FDA approval for first in class drugs from 1999–2013 and reported a median interval of 22 years [26].”
Background
Cited by
Medical Micro/Nanorobots in Precision Medicine
Soto, F., Wang, J., Ahmed, R., & Demirci, U. (2020) · Advanced Science · doi:10.1002/advs.202002203 · Cited by 442
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Contribution of NIH funding to new drug approvals 2010–2016
Galkina Cleary, E., Beierlein, J. M., Khanuja, N. S., McNamee, L. M., & Ledley, F. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715368115 · Cited by 248
Self-citationNIH funding for vaccine readiness before the COVID-19 pandemic
Kiszewski, A. E., Cleary, E. G., Jackson, M. J., & Ledley, F. D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.022 · Cited by 38
“Evidence also shows that the timelines of clinical development from Phase 1 to approval is significantly shorter when clinical trials commence after the underlying technologies have passed this point [20,21].”
BackgroundMethodSelf-citationBeierlein, J. M., McNamee, L. M., Walsh, M. J., Kaitin, K. I., DiMasi, J. A., & Ledley, F. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.001 · Cited by 24
“These studies also suggest that timelines of clinical and regulatory development are shorter when clinical trials began after the established point than when clinical trials begin before this point.(43) Prior reviews of cardiovascular drug development focused on aspects of the biology and pharmacology of CVD and the l…”
BackgroundResultSelf-citation
Metadata
- Authors
- McNamee, L. M., Walsh, M. J., & Ledley, F. D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-05-08
- Volume
- 12
- Issue
- 5
- Pages
- e0177371
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2612115802
- Cited by
- 54
- References
- 5
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Timelines of translational science: From technology initiation to FDA approval. https://app.cochat.ai/papers/10.1371/journal.pone.0177371
- The paper
- McNamee, L. M., Walsh, M. J., & Ledley, F. D. (2017). Timelines of translational science: From technology initiation to FDA approval. PLOS ONE. https://doi.org/10.1371/journal.pone.0177371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.